AwardTape / Contracts / W81XWH-15-D-0037
W81XWH-15-D-0037: Defense Health Agency Award to Dynport Vaccine Company LLC
Igf::ot::igf - research&development in support of the us ARMY medical materiel development activity (usammda) for the performance of a phase i, multi-center, randomized, double-blind, placebo-controlled study to assess the long-term .... Contracting activity: ARMY MED RES ACQ ACTIVITY. Estimated completion: 2022-07-31.
$24.2M cumulative ceiling / COMPETITION NOT STATED / 2022-07-31 completion / W81XWH ARMY MED RES ACQ ACTIVITY
1. Contract Summary & Primary Sources
| Contract Number (PIID) | W81XWH-15-D-0037 (unhyphenated: W81XWH15D0037) |
|---|---|
| Prime Contractor (Awardee) |
Dynport Vaccine Company LLC
FY2024-FY2026 Federal Defense Portfolio: -$96.1M obligated across 4 contracts
|
| Obligated Amount | Order-Dependent / TBD |
| Cumulative Face Value / Ceiling | USAspending Base IDV Ceiling: $24,245,008 |
| USAspending / FPDS Obligation History | Base Record Obligated: -$223,902 (signed 2017-03-22, latest FPDS action 2026-01-23) |
| Awarding Branch / Agency | Defense Health Agency |
| Contracting Command & DoDAAC | W81XWH: ARMY MED RES ACQ ACTIVITY |
| Competition & Contract Structure | COMPETITION NOT STATED · Delivery Order / Cost-Plus-Fixed-Fee (CPFF) |
| Product / Service & Industry Codes | PSC AJ53 (R&D- General Science/Technology: Life Sciences (Advanced Development)) · NAICS 541712 (Research And Development In The Physical, Engineering, And Life Sciences (Except Biotechnology)) |
| Work Locations & Funding | Determined at the contract or task-order level |
| Estimated Completion Date | 2022-07-31 |
| Verified Primary Sources |
2. Verbatim Announcement & Scope Breakdown
Igf::ot::igf - research&development in support of the us ARMY medical materiel development activity (usammda) for the performance of a phase i, multi-center, randomized, double-blind, placebo-controlled study to assess the long-term ...
3. Subcontractor, Supply Chain & Capture Intelligence
Subcontracting & Material Supply Window
- Prime Awardee: Dynport Vaccine Company LLC
- Delivery Runway: Active through 2022-07-31
- Requirement Scope: Igf::ot::igf - research&development in support of the us ARMY medical materiel development activity (usammda) for the performance of a phase i, multi-center, randomized, double-blind, placebo-controlled study to assess the long-term ...
- Federal Supply Class: PSC AJ53 (R&D- General Science/Technology: Life Sciences (Advanced Development))
- BD Action: Reference Prime Contract W81XWH-15-D-0037 when contacting Dynport Vaccine Company LLC Supply Chain / Small Business Liaison Officer.
Buying Command & Recompete Posture
- Buying Command: W81XWH (ARMY MED RES ACQ ACTIVITY)
- Acquisition Method: COMPETITION NOT STATED
- FOIA Jurisdiction: Army Contracting Command (ACC) FOIA Officer (usarmy.redstone.acc.mbx.hqaccfoia@army.mil)
- Capture Action: Request Section B CLIN ceiling structure and Section C Statement of Work below to benchmark deliverable requirements.
4. Underlying Contract Files (Section B Pricing & Section C Statement of Work)
Pre-Filled FOIA Request Letter for W81XWH-15-D-0037
Routed to Army Contracting Command (ACC) FOIA Officer (usarmy.redstone.acc.mbx.hqaccfoia@army.mil) · Official Agency FOIA Portal ↗